University of Montana

ScholarWorks at University of Montana
Biomedical and Pharmaceutical Sciences Faculty
Publications

Biomedical and Pharmaceutical Sciences

1994

Functional comparisons of three glutamate
transporter subtypes cloned from human motor
cortex
Jeffrey L. Arriza
Wendy A. Fairman
Jacques I. Wadiche
Geoffrey H. Murdoch
Michael Kavanaugh
See next page for additional authors

Let us know how access to this document benefits you.
Follow this and additional works at: https://scholarworks.umt.edu/biopharm_pubs
Part of the Medical Sciences Commons, and the Pharmacy and Pharmaceutical Sciences
Commons

Authors

Jeffrey L. Arriza, Wendy A. Fairman, Jacques I. Wadiche, Geoffrey H. Murdoch, Michael Kavanaugh, and
Susan G. Amara

The Journal of Neuroscience,

Functional Comparisons of Three Glutamate
Cloned from Human Motor Cortex
Jeffrey L. Arriza, Wendy A. Fairman,
Susan G. Amara
The Vellum Institute for Advanced

Jacques

Biomedical

I. Wadiche,

Research,

Geoffrey

Transporter

H. Murdoch,

Oregon Health Sciences

Reuptake plays an important role in regulating
synaptic and
extracellular
concentrations
of glutamate.
Three glutamate
transporters
expressed
in human motor cortex,
termed
EAATl , EAATP, and EAAT3 (for excitatory amino acid transporter), have been characterized
by their molecular
cloning
and functional expression.
Each EAAT subtype mRNA was
found in all human brain regions analyzed. The most prominent regional variation in message content was in cerebellum where EAATl
expression
predominated.
EAATl
and
EAAT3 mRNAs were also expressed
in various non-nervous
tissues, whereas expression
of EAATS was largely restricted
to brain. The kinetic parameters
and pharmacological
characteristics
of transport
mediated
by each EAAT subtype
were determined
in transfected
mammalian
cells by radiolabel uptake and in microinjected
oocytes by voltage-clamp
measurements.
The affinities of the EAAT subtypes for L-glutamate were similar, with K, determinations
varying from 48
to 97 AM in the mammalian
cell assay and from 18 to 28 NM
in oocytes. Glutamate
uptake inhibitors
were used to compare the pharmacologies
of the EAAT subtypes. The EAAT2
subtype was distinguishable
from the EAATl /EAAT3 subtypes by the potency of several inhibitors,
but most notably
by sensitivity to kainic acid (KA) and dihydrokainic
acid (DHK).
KA and DHK potently inhibited EAATP transport,
but did not
significantly
affect transport
by EAATl /EAAT3. Using voltage-clamp measurements,
most inhibitors
were found to be
substrates that elicited transport
currents.
In contrast,
KA
and DHK did not evoke currents and they were found to block
EAATP-mediated
transport
competitively.
This selective interaction with the EAATP subtype could be a significant
factor in KA neurotoxicity.
These studies provide a foundation
for understanding
the role of glutamate
transporters
in human excitatory neurotransmission
and in neuropathology.
[Key words: glutamate
transporter,
uptake, amino acids,
human, molecular cloning, inhibitor, pharmacology,
kainate,
neurotoxicity]

Uptake of the acidic amino acidsglutamate and aspartatefrom
the extracellular environment is mediatedby sodium-dependent
transport systemsof high affinity that are found in both the
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peripheral tissues(Christensen,1990)and in the nervous system
(Kanner and Schuldiner, 1987; Nicholls and Attwell, 1990).
Transport serves a special function in the brain by mediating
the reuptake of glutamate releasedat excitatory synapses.Glutamate can be reaccumulated from the synaptic cleft by the
presynaptic nerve terminal (Eliasof and Werblin, 1993) or by
glial uptake of transmitter diffusing from the cleft (Nicholls and
Attwell, 1990; Schwartz and Tachibana, 1990; Barbour et al.,
1991).The activities of neuronal and glial transportersinfluence
the temporal and spatial dynamics of the chemical signal in
other neurotransmitter systems(Hille, 1992; Bruns et al., 1993;
Isaacsonet al., 1993), but such effects have not yet been demonstrated at glutamatergic synapses(Hestrin et al., 1990; Sarantis et al., 1993).
Glutamate is a potent neurotoxin and transporter-mediated
uptake serves to maintain extracellular glutamate concentrations below toxic levels. Just as the neurotoxic potency of glutamate is diminished by uptake (Choi et al., 1987; Rosenberg
et al., 1992) the neurotoxicity of other excitatory amino acids
may also be influenced by the nature of their interaction with
glutamate transporters The pharmacology of glutamate transporters have beenextensively investigated (Balcar and Johnston,
1972; Ferkany and Coyle, 1986; Fletcher and Johnston, 1991;
Robinson et al., 1991; Rauenet al., 1992; Robinson et al., 1993)
and exhibits a considerable degree of overlap with the pharmacologyofglutamate receptors(Chamberlinand Bridges,1993).
Thus, many of the agents that inhibit glutamate uptake are
structural analogsofexcitatory amino acidsthat act asglutamate
receptor agonists,and whether the compound is a transporter
substratecan be an important determinant of its neurotoxicity.
The neurotoxic potency of kainic acid (KA), for example, may
be enhancedbecauseit is not taken up (Johnston et al., 1979).
Regional differences in the potencies of various glutamate
uptake inhibitors have suggestedthe existence of multiple glutamate transporter subtypes(Ferkany and Coyle, 1986;Fletcher
and Johnston, 1991; Robinson et al., 1991; Rauen et al., 1992;
Robinson et al., 1993) but a subtype pharmacology has been
difficult to establish becauseof the complex nature of uptake
systemsin the brain slice, synaptosomes,or other membrane
preparations used. An essentialstep toward understandingthe
contribution of uptake to the toxicity of excitatory amino acids
is the determination of the properties of each transporter subtype.
A genefamily that mediatesthe cellular uptake of acidic and
neutral amino acids in mammals has recently been defined by
molecular cloning (for reviews, seeAmara and Arriza, 1993;
Kanner, 1993; Kanai et al., 1993). Three subtypes of high-affinity glutamate transporters were cloned independently (Kanai
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and Hediger, 1992; Pines et al., 1992; Storck et al., 1992; Tanaka, 1993) and sequence comparisons revealed extensive
regions of amino acid sequence conservation. Particularly striking was the conservation of an amino acid sequence AA(I/
V)FIAQ found in the mammalian glutamate transporters but
also in prokaryotic glutamate and dicarboxylate carriers. We
have utilized degenerate oligonucleotides based upon this sequence conservation to isolate related transporter cDNAs from
human brain. Recently, we reported the cloning and functional
characterization of a neutral amino acid transport system that
is also a member of the glutamate transporter gene family defined by the AA(I/V)FIAQ
structural motif (Arriza et al., 1993).
This same approach has led to the cloning of three excitatory
amino acid transporters, EAATl, EAAT2, and EAAT3, which
are similar to the transporters previously isolated from rat and
rabbit. Here, we report the st-ructure, distribution, functional
expression, and pharmacology of these human EAAT subtypes.

Materials

and Methods

cDNA cloning, sequenceanalyses, andplasmid constructions. A synthetic
oligonucleotide complementary to a portion of GLASTl (Storck et al.,
1992; residues 395-l 15, ATINMDGTALYEALAAIFIAQ)
was synthesized as a hybridization probe. This oligonucleotide sequence 15’
CTG (A/G)GC (A/G)AT GAA (A/G)AT GGC AGC CAG GGC (C/
T)TC ATA CAG GGC TGT GCC (A/G)TC CAT GTT (A/G)AT GGT
(A/G)GC 3’1 is 128fold degenerate and utilizes human codon preferences. Human motor cortex RNA was isolated by the method of Chomczynski and Sacchi (1987) and polyA+ enriched by oligo(dT)-cellulose
chromatography. Mixed oligo(dT)-primed
and random-primed cDNA
was synthesized from this RNA using the Superscript Choice System
(Bethesda Research Labs, Gaithersburg, MD) and ligated into XZAPII
(Stratagene, La Jolla, CA) to obtain a human cortex cDNA library
(termed XZAP-hMC) with a complexity of 1 x 106 independent clones
and an average insert size of - 2 kilobases (kb). XZAP-hMC was screened
with 32P-labeled oligonucleotide using the following conditions for hybridization and wash: 1 x lo6 cpm/ml in 0.5 M Na,HPO,, pH 7.15,
7% SDS for hybridization at 50°C and wash at 60°C in 2 x SSPE (20 x
SSPE = 3 M NaCl, 0.2 M NaH,PO,, 0.02 M Na,EDTA, pH 7.4) and 1%
SDS. Plasmids were obtained from purified plaques by in vivo excision
(Stratagene, La Jolla, CA) and sequenced on both strands using doublestranded template, synthetic oligonucleotide primers (Oligos Etc.), 35SdATP (New England Nuclear-Du Pont, Natick, MA), and Sequenase
2.0 (United States Biochemical Corp., Cleveland, OH). Sequence data
analysis was performed using MACVECTOR
(IBI, New Haven, CT). The
plasmids termed pEAAT 1, pEAAT2, and pEAAT
contained cDNA
inserts 4.1 kilobase pairs (kbp), 2.5 kbp, and 3.4 kbp, respectively.
pEAAT and pEAAT
contained in-frame termination codons at the
5’ end of their open reading frames and the nucleotide sequences surrounding the first downstream methionine codon conform to consensus
translation initiation sites. No in-frame termination codons were found
in the 15 nucleotides upstream of the proposed initiator methionine of
pEAAT3, but this sequence also conforms to the consensus initiation
sequence and is similar to that reported for the rabbit transporter EAACI
(Kanai and Hediger, 1992).
The coding sequences of each EAAT subtype were isolated from
cDNAs by the polymerase chain reaction (PCR). Thirty cycles of denaturation (1 min, 94”C), annealing (1 min, 5S°C), and extension (2 min,
72°C) were performed in 100 bl reactions that contained oligonucleotide
primers at 1 PM each, 10 ng of plasmid cDNA template, 300 PM each
deoxynucleotide, Vent polymerase and reaction buffer (New England
Biolabs). Unique Ranking restriction sites (Asp7 18 and Xbal for EAATl
and EAAT2, Asp7 18 and BamH 1 for EAAT3) were incorporated into
the oliaonucleotide mimers. Primer seouences (5’ to 3’) were CGCG
GGTACC AAT ATG ACT AAA AGC AAT G and CGCG TCTAGA
CTA CAT CTT GGT TTC ACT G for EAAT 1, CGCG GGTACC ACC
ATG GCA TCT ACG GAA G and CGCG TCTAGA TTA TTT CTC
ACG TTT CCA AG for EAATZ, CGCG GGTACC GCC ATG GGG
AAA CCG GCG and CGCG GGATCC CTA GAA CTG TGA GGT
CTG for EAAT3. Digestion of the reaction products with the appropriate restriction enzymes allowed each coding sequence to be subcloned
into expression plasmids.

The PCR-generated coding sequences were subcloned into the expression plasmid pCMV5 (Andersson et al., 1989) to generate constructs
(termed pCMV-EAATI,
etc.) for functional analyses in transfected
mammalian COS-7 cells. EAAT subtype coding sequences were also
subcloned into pOTV for expression in Xenopus laevis oocytes. pOTV
is an oocyte transcription vector utilizing the T7 polymerase promoter
for in vitro transcription of RNA. The coding sequences were inserted
between Xenopus fl-globin 5’- and 3’-untranslated regions derived from
pSP64T (Krieg and Melton, 1984) to enhance expression levels in oocytes. The resulting expression plasmids are termed pOTV-EAAT 1, etc.
Northern blot analysis. Human brain region RNAs were prepared
(Chomczynski and Sacchi, 1987) from tissue provided by the Oregon
Brain Repository. RNAs were size fractionated on denaturing formaldehyde gels and transferred to nylon membrane. The human peripheral
tissue Northern blot was obtained from Clontech Laboratories. The
coding sequences of EAATl, EAAT2, and EAAT3 were excised and
radiolabeled with &*P-dCTP
(New England Nuclear) by the random
priming method (Boehringer Mannheim). Filters were hybridized overnight ai 42°C with cDNA probe ( lo6 cpm/ml) in 5 x SSPE, 50% formamide, 7.5 x Denhardt’s solution, 2% SDS, and 100 mg/ml of denatured salmon sperm DNA. Autoradiography was performed after two
30 min room temperature washes in 2 x SSPE, 1.O% SDS, and two 20
min washes at 50°C in 0.1 x SSPE. 0.1% SDS.
Cell transfections and transport &rays. COS-7 cells were maintained
in DMEM with 10% fetal calf serum at 5% CO,. Each EAAT subtype
was expressed independently by DEAE dextran-mediated transfection
of COS-7 cells with the appropriate expression plasmid (for example,
pCMV-EAATl).
Transfection of pCMV-5 was used to control for the
level of endogenous uptake of radiolabeled L-glutamate (or D-aspartate)
in each experimental condition. Subconfluent COS-7 cells were plated
at a density of - 100,000 cells per well in 12-well tissue culture plates
and transfected the following day with 0.5 pg of plasmid DNA per well
essentially as described (Lopeta et al., 1984). Two days posttransfection,
the cells are washed three times with 0.5 ml of room temperature D-PBS
(2.7 mM KCl, 1.2 mM KH,PO,, 138 mM NaCl, 8.1 mM Na2HP04, pH
- 7.4) over a period of 10 min prior to the uptake assays.
Uptake of radiolabeled substrate or substrate plus inhibitor was assessed at room temperature in 0.5 ml of D-PBS. It was determined that
with a substrate concentration of 1 mM the uptake rate was linear for
at least 20 min. Routinely, assays were terminated after 10 min. To
terminate uptake, cells were washed three times with ice cold PBS and
solubilized in 0.5 ml of 0.1% SDS prior to scintillation counting in 5
ml of ScintiVerse (Fisher Scientific). All assays contained 100 nM 3Hr+lutamate or 3H-D-aspartate diluted as necessary with cold substrate.
Affinity constant (K,,) determinations measured uptake at 12 different
substrate concentrations, while inhibitor constant (K,) measurements
contained 1 PM glutamate and 12 different inhibitor concentrations. All
points were assayed in triplicate. Data was analyzed using KALEIDAGRAPH
(Synergy Software, Reading, PA) for a least-squares fit to the
Michaelis-Menten
equation and an Eadie-Hofstee transformation. Calculated I’,,,, values (in pmol/well/min)
varied in independent experiments from 5 1 to 5 13 for EAATl, 111 to 894 for EAAT2, and 152 to
624 for EAAT3. Inhibition data were fitted to the Michaelis-Menten
equation to determine the 100% of control value and the IC,,. Since
the K, calculated using the method of Cheng and Prusoff (1973) does
not differ significantly from the determined IC,,, these values are presented as K, values. All values provided are the mean -+ SEM of at least
three determinations.
Pharmacological
agents. Dihydrokainate,
kainate, m-threo-&hydroxyaspartic acid, L-cysteine sulfinic acid, N-methyl-D-aspartate, L-serine-U-sulfate, t-aspartate-@-hydroxymate,
@-glutamic acid, L-a-aminoadipic acid, L- and D-glutamate, L- and D-aspartic acid, and t-cysteine
were obtained from Sigma. Quisqualate, trans-(dicarboxyl)-2,4-methanoglutamic acid, cis-(dicarboxyl)-2,4-methanoglutamic
acid, (f&pchlorophenylglutamic
acid, and S-sulfo-L-cysteine were from Tocris
Neuramin (Bristol, UK). L-Trunk-pyrrolidine-2,4-dicarboxylic
acid and
(a-&oxalyl-a,&diaminopropionic
acid were from Research Biochemicals Inc. (Nat&k, MA). NIacetyl-L-aspartyl-L-glutamate
was from Bachem Bioscience (Philadelphia, PA). JH-L-glutamate (19.2 Ci/mmol), 3HD-aspartate (2 1 Ci/mmol), and 3H-kainate (58 Ci/mmol) were obtained
from New England Nuclear-Du Pont (Natick, MA).
Expression of EAAT subtypes in oocytes. Synthetic RNA was transcribed in vitro from pOTV-EAAT 1, pOTV-EAATZ,
or pOTV-EAAT3
as described (Arriza et al., 1993) and injected into defolliculated stage
V-VI Xenopus oocytes. Two to seven days following injection, transport
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Figure 1. Alignment of the amino acid sequences of the human excitatory amino acid transporters EAATl , EAAT2, and EAAT3. The amino
acid sequences deduced from cDNA nucleotide sequences are depicted. Gaps (dots) have been introduced to facilitate this alignment. Sequence
identities are indicated by using whiteon blackletteringat positions where at least two of the three aligned sequences predict identical amino acid
residues. Barsare drawn over nine regions of extensive sequence hydrophobicity that may correspond to transmembrane or membrane-associated
structures. Potential sites of N-linked glycosylation (N-X-S/T) are indicated by circlingthe relevant asparagine (N) residues. The nucleotide sequences
of EAATl, EAAT2, and EAAT3 may be obtained from the GenBank database under accession numbers UO3504, UO3505, and UO3506,
respectively.
was measured by two-electrode voltage-clamp recording using a Dagan
TEV-200 clamp amplifier with an Axon Instruments TL- 1 A/D interface. Oocytes were voltage clamped at -60 mV and continuously superfused with ND-96 buffer (96 mM NaCl, 2 mM KCl, 1.8 mM CaCP,
1 mM MgCl,, and 5 mM HEPES pH 7.5). For transport measurements,
this buffer solution was changed to one containing the indicated concentration of substrate. Current (Z) as a function of substrate concentration ([SJ) was fitted by least squares to Z = I,,,,. . [Sj/(K, + [S]) where
I,,,,, is the maximal current and K,, is the Michaelis transport constant.
Values of K,, and I,,,,, are expressed as mean + SEM and were determined by fitting data from individual oocytes. The I,,,,, values for transporter substrates are expressed as the I,,,,, relative to that determined
for L-glutamate in the same cells. The antagonism of EAAT2 transport
by kainic acid and dihydrokainic acid was evaluated using Schild analysis (Arunlakshana and Schild, 1959).

Results
Molecular cloning of EAA TI, EAA T2, and EAA T3 from
human cortex
The three human glutamatetransporterscharacterizedhere were
isolated as cDNAs from a human motor cortex library using a
degenerateoligonucleotide probe (seeMaterials and Methods).
The plasmidspEAAT 1, pEAAT2, and pEAAT contained distinct cDNA sequences
with large open reading framesidentified
by nucleotide sequenceanalysis. The predicted amino acid sequencesof the encoded proteins, termed EAATl, EAAT2, and
EAAT3, are 542, 574, and 525 amino acids in length, respectively, as shown

in Figure

1. The theoretical

molecular

weights

of EAATl, EAAT2, and EAAT3 are 59.5, 62.1 and 57.2 kDa.
On the basisof nucleic acid and amino acid sequencehomology,
EAAT 1, EAAT2, and EAAT3 could correspond to glutamate
transporters previously isolated from other species.EAAT 1 has
96% amino acid sequenceidentity with the rat GLASTl sequence (Storck et al., 1992). Similarly,

EAAT2

has 95% identity

with the corrected sequence(Kanner, 1993) of rat GLT 1 (Pines
et al., 1992) and EAAT3 has 92% identity with the rabbit
sequencetermed EAAC 1 (Kanai and Hediger, 1992). However,
recent evidence

suggests the existence

of at least two additional

human glutamate transporter subtypes, one of which is strikingly similar to both EAATl and GLASTl (W. Fairman, unpublished data). Thus it is possiblethat EAATI is a novel subtype rather than the human homolog of GLASTI.
Alignment of the EAAT protein amino acid sequencesillustrates the extensive conservation of both primary sequenceand
other structural features within this gene family. The N- and
C-termini differ in sequenceand in length, but 70% of the positionsin the region where thesethree protein sequences
overlap
are identical in at leasttwo of the three sequences.Accordingly,
the hydropathy profiles of the EAAT subtypesare very similar
when algorithms designed to identify transmembrane helices
are utilized (Engelmanet al., 1986), and nine major regionsof
amino acid sequencehydrophobicity have been indicated in
Figure 1. However, predictions of the secondary structure of
theseregionsare often more consistentwith ,&sheetsthan a-hel-
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Expression
of EAAT subtypemRNAsin humantissues.
A, Northernblot analyses
of RNAs preparedfrom dissected
brainregionswith
radiolabeled
codingsequences
for eitherEAATl, EAATZ, or EAAT3. Eachlanecontainsapproximately20pgof total RNA, andthe autoradiograms
wereexposed12hr for EAATl andEAAT2, and24 hr for EAAT3. The estimatedsizeof eachmRNA in kilobases
(kb) is indicated.Hybridization
of a humanP-actincDNA probeto a parallelblot suggests
that the motor cortex lanecontainsmoreRNA than the otherlanes.B, A singleblot
containingapproximately2 pg of polyA+ RNA from eachindicatedhumantissuewassuccessively
hybridizedwith eachEAAT cDNA probe.The
samefilter wasalsoreprobedwith a humanP-actincDNA to normalizefor relative mRNA loading.@-ActinmRNA is approximately2.0 kb in
length,but heartandskeletalmusclecontainan abundant1.7kb actin mRNA species
that alsohybridizes.

Figure 2.

ices, and the actual number of transmembraneor membraneassociateddomains has not been established.The amino terminus is likely to be intracellular sincethere is no signalpeptide
sequence,and the conservation in each subtype of potential
N-linked glycosylation sites between the third and fourth hydrophobic regions (Fig. 1) suggeststhat this domain is extracellular.

RNA distribution by Northern blot analyses
Northern blot analysis of RNAs prepared from a variety of
human tissueswas usedto determine the distribution of EAAT
subtype mRNAs. The subtype mRNA content was compared
in five human brain regions (Fig. 2A). Hybridization with an
EAATl probe revealed a -4.2 kb mRNA relatively abundant
in all regionsexamined, but significantly enriched in the cerebellum. In contrast, EAAT2 mRNA (- 10.0 kb) was poorly
representedin the cerebellarpreparation, but wasvery abundant
in other brain regions.In contrast to the multiple RNA species
reported for EAACl (Kanai and Hediger, 1992), a single hybridizing band (-3.8 kb) was seen with the EAAT3 cDNA
probe, and this band was found at low levels and in a pattern
similar to that observedfor the constitutively expressed,&actin
mRNA. Although the rabbit transporter EAACl has been reported to exhibit a neuronal pattern of expression(Kanai and
Hediger, 1992), EAAT3 mRNA content did not differ significantly between regions such as the hippocampus that have a
high density ofglutamatergic neurons,and a regionlike the basal
gangliathat has few glutamatergic neurons (Fig. 2A).
The expressionof EAAT subtypesin various human peripheral tissueswas also examined (Fig. 2B). EAATl RNA was
nearly asabundant in heart and skeletalmuscleasin brain, and
was also detectable in placenta and lung. This result contrasts
with the reported brain-specific distribution of the structurally
similar rat GLASTl (Storck et al., 1992). The distribution of
EAAT2 mRNA, like GLTl (Pineset al., 1992), was rather restricted; asidefrom brain, detectable levels were found in only
one other tissueexamined, the placenta.EAAT3 RNA wasmost
abundant in kidney with lower levels in brain, lung, and pla-

centa, and messagedetectable in liver, muscle, and heart. The
low level of EAAT3 expression in lung and heart also differs
somewhatfrom the reported distribution of EAACl (Kanai and
Hediger, 1992).

Functional expression in mammalian

cells

Functional characterization of the EAAT subtypes was performed by transient expressionin mammalian cells.The coding
sequencesof each subtype cDNA were inserted into the COS
cell expression plasmid pCMV5, and the resulting constructs,
pCMV-EAAT 1, pCMV-EAAT2, and pCMV-EAAT3, were
transfected into COS-7 cells. This expressionsystem provided
levels of radiolabeled substrate uptake significantly ( 1O-l OOfold) greater than that of endogenousCOS-7 cell uptake. Endogenousuptake was measuredin parallel control experiments
in which COS-7 cellswere transfectedwith the parental pCMV5
plasmid, and subtracted from each data point. Each assaypoint
was performed in triplicate and each experiment wasperformed
at least three times.
The kinetics of the cellular uptake of the glutamatetransporter
substrates L-glutamate and D-aspartate were examined for
EAATl, EAAT2, and EAAT3 (Fig. 3). Uptake (in pmol/well/
min) asa function of substrateconcentration wasfitted by leastsquaresto the Michaelis-Menten equation, and the half-maximal transport constant (K,) was determined using the EadieHofsteetransformation (insets,Fig. 3). The K,,, valuesof EAATl,
EAAT2, and EAAT3 for uptake of L-glutamate were 48 + 10,
97 + 4, and 62 f 8 PM, respectively (Fig. 3A,C,E). Uptake of
the nonmetabolized amino acid D-aspartateyielded K, values
of 60 f 12, 54 + 9, and 47 _+9 PM for EAATl, EAAT2, and
EAAT3, respectively (Fig. 3B,D,F). Subtype I’,,,, determinations could not be directly compared in this assaysystem becauseof the dependenceon efficiency of transfection and other
factors related to the level of expression. The I’,,,, of a single
subtype was observed to vary as much as IO-fold between experiments, and without specific antibodies or high affinity ligandsit is not possibleto compare the level of expressionof a
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particular subtype. There was no evidence, however, that the
transport K,,, was affected by expressionlevel.
Pharmacological characterization of the EAA T subtypes
The pharmacologicalproperties of the human glutamate transporter subtypes were characterized in assayssimilar to those
describedabove, but with a fixed concentration of radiolabeled
glutamate (1 PM) and varying drug concentrations. Candidate
drugs were initially tested at three concentrations (3 PM, 100
PM, 3 mM) to determine their potency and specificity. This threepoint screen was subsequentlyfound to provide approximate
K, values generally consistent with those determined by more
complete (6-12 point) assays.The following compounds were
only characterized by three-point assays.HgCl, was a potent
inhibitor of EAATI, EAAT2, and EAAT3 (K, = 31 PM, 99 PM,

(uM)

Figure 3. Excitatory amino acid uptake by EAAT subtypesexpressedin
transfectedCOS-7 cells. The kinetic
propertiesof the cellularuptakeof )HL-glutamate
(A, C,E) or 3H-o-aspartate
(B, D, E) as mediatedby EAATl (A,
B), EAATZ (C, D), or EAAT3 (E, F)
wereassessed
by the transientexpressionof thesetransporters
in COS-7cells.
Uptakevelocity (in pmol/well/min)was
measured
using100nMof radiolabeled
aminoacid and increasingconcentrationsof unlabeledaminoacid.Thedata
presented
arethe meanof triplicatedeterminationsfrom singlerepresentative
experiments,and individual determinationsfor eachpointdid notvary from
the meanby > 20%.K,” valueswereobtainedfrom theEadie-Hofstee
plots(insets),and the valuespresented
are the
mean* SEMof at leastthreeindependent experiments.

and 62 FM, respectively; n = 2). Trans-(dicarboxyl)-2,4-methanoglutamic acid, an uptake inhibitor reported to be relatively
inactive at glutamate receptors(Fletcher et al., 199l), provided
K, estimatesof 120 f 21, 660 f 153, and 244 + 94 PM (n =
3) for EAATl, EAAT2, and EAAT3. Its stereoisomer[cis-(dicarboxyl)-2,4-methanoglutamic acid], a NMDA receptor agonist (Lanthom et al., 1990) did not inhibit uptake. Compounds
with determined K, values of 2 1 mM in this assaysystemwere
defined as inactive. Other inactive compounds were NMDA,
quisqualate, (S)-P-oxalyl-cY,p-diaminopropionic acid (ODAP);
(*)/3-p-chlorophenylglutamic acid, N-acetyl aspartylglutamate
(NAAG), L-cysteine,and S-sulfo-L-cysteine. L-cu-Aminoadipate,
a classicalinhibitor of glutamate uptake in rat (Balcar and Johnston, 1972), was eiamined asan inhibitor of the EAAT subtype
and the measuredK, values were > 1 mM.
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Table 1. Glutamate uptake inhibition

2 o-

1

10

100

1000

10000

lOrue PM

Cornpour&

K, determined (in PM)
EAATl
EAAT2

TPHA
PDC
SOS
DHK
KA
CA
LCSA
@-Glu
LA@H

32 + 8
79 k 7
107 + 8
23 mM
>3 mM
10 & 3
14 + 7
297 + 118
369 + 70

6
275
6
18
2
37
27

25 + 5
61 + 14
150 + 52
>3 mM
>3 rnM
19 k 9
17 f 2
307 k 48
133 k 34

Table 1 also lists the abbreviations and full chemical namesof
theseinhibitors. TpHA and PDC were potent inhibitors of each
subtype, but PDC wasmore potent than T@HA on EAAT2 while
TPHA wasmore potent than PDC on EAAT 1 and EAAT3. KA
and DHK inhibited EAAT2 uptake with K, values of 59 + 18
PM and 23 -t 6 PM, respectively, but had no significant effect
on the activity of EAATl and EAAT3 at concentrations less
than 1 mM. In contrast, SOSinhibited EAATl and EAAT3 with
K, values of 107 + 8 pM and 150 f 52 PM, but wasdetermined
to have a K, of 1157 f 275 I.LM for inhibiting uptake by EAAT2.
Thus, the rank order of potency for EAAT2 was(from the lowest
K,) PDC < TpHA < DHK < KA < SOS, whereasthe rank
order of potency for EAATl and EAAT3 was TPHA < PDC
< SOS < DHK, KA (Fig. 4, Table 1). One drug moderately
useful for discriminating between EAATl and EAAT3 was
LAPH, with K, values of 369 f 70 I.LM and 133 f 34 PM,
respectively.

EAATB

Electrogenic
oocytes
20-

1

19 +
8*2
1157 k
23 +
59 +
10 +
6+1
156 f
184 f

EAAT3

a TBHA, DL-threo+hydroxyaspartic
acid; PDC, L-trans-pyrrolidine-2,4-d&wboxylic acid; SOS, L-serine-O-sulfate;
DHK, dihydrokainic
acid; KA, kainic acid;
CA, L-cysteic acid; LCSA, L-cysteine sultinic acid; @-Glu, b-glutamate;
L&H,
L-aspartate-@-hydroxymate.

B. EAATP

C.

constants

10

100
t0w1

1000

10000

PM

Figure 4. Pharmacology of EAAT subtypes expressed by COS cell
transfection. The potencies of glutamate uptake inhibitors were assessed
in COS cells transfected with either EAATl (A), EAATZ (B), or EAAT3
(C). Uptake of 1 PM ‘H L-glutamate was assessed in the presence of the
indicated amount of inhibitor. Inhibitors were TBHA (solid squares),
PDC (solid triangles), SOS (solid circles), DHK (open diamonds), and
KA (solid diamonds). DHK and KA had no significant effect on EAAT land EAAT3-mediated uptake at concentrations 5 1 mM (data not shown).
Each data set shown is from a single representative experiment performed in triplicate with individual determinations varying from the
mean by ~20%. The K, values listed in Table 1 are from at least three
independent experiments (mean f SEM). Chemical names of the compounds abbreviated above are given in Table 1.

Potentially selective and/or potent inhibitors were more extensively characterized by full K, determinations. Representative data for the effect of five uptake inhibitors (TBHA, PDC,
SOS, DHK, and KA) on transport by each EAAT subtype are
presentedin Figure 4, and K, values are provided for theseand
other inhibitors (CA, LCSA, P-GLU, and LAPH) in Table 1.

transport

of glutamate

and analogs

in Xenopus

Superfusion of voltage-clamped oocytes expressingthe human
EAAT subtypeswith L-glutamate and other substratesresulted
in inward currents that were dose dependent, saturable, and
required the presenceof sodium in the superfusionmedia (Fig.
5A). Kinetic parameterswere determined by measuringthe concentration dependenceof the uptake currents (Fig. 5B). The
transport mediated by each EAAT subtype was characterized
for each glutamate and aspartate stereoisomer,and for several
uptake

inhibitors

(Table

2). Transport

was stereospecific

for

L-glutamate but not for D- or L-aspartate, a characteristic of
these sodium-dependent uptake systems(Kanner and Schuldiner, 1987). The K,,, values obtained in this assaysystemwere
similar to those determined by measuringthe uptake of )H-Lglutamate and 3H-D-aSpartate
in COS-7 cellsexpressingEAAT
subtypes (compare Table 2, Fig. 3), although the affinity constantsdetermined in oocyteswere, in general,significantly lower
than those measuredin mammalian cells. The maximum current (I,,,,,) associatedwith the uptake of substrateswas also
compared by normalizing I,,,., values to the maximum current
obtained with L-glutamatein the sameoocyte. TheseZ,,,,,values
varied for each substrate, and the I,,,,, values for a particular
substratevaried between subtypes. Subtype-specific variations
in I,,, values were most dramatic for D-glutamate (Table 2).

The Journal

Glutamate uptake inhibitors such as PDC (Fig. 5A) and TOHA
also elicited transport currents, and the K,,, values determined
by electrophysiology were comparable to the K, values determined by uptake competition in COS-7 cells (compare Tables
1, 2).
Mechanism of inhibition of EAAT2 uptake by KA and DHK
Most inhibitors of glutamate uptake were found to evoke inward
currents. In contrast, superfusion with KA did not evoke currents in voltage-clamped oocytes expressing any of the EAAT
subtypes, suggesting that this compound is not a transport substrate (Fig. 6A). Moreover, the coadministration of KA did not
affect the uptake currents elicited by L-glutamate in oocytes
expressing either EAAT 1 or EAAT3, in agreement with the lack
of KA effect on 3H-glutamate uptake in transfected COS cells
expressing these subtypes (Table 1) . However, the EAAT2 glutamate-induced uptake current in oocytes was significantly reduced in the presence of KA (Fig. 6A). Similar results were
obtained with the KA analogue DHK. To rule out the possibility
that KA and DHK were transported by EAATZ via a nonelectrogenic mechanism, radiolabeled KA uptake (at 1 MM) was
compared to L-glutamate uptake (at 1 PM) in parallel assays of
EAAT2-expressing and control COS-7 cells. Less than 0.1 pmol/
well/min of KA uptake was measured, as compared with 44.3
pmol/well/min
of specific L-glutamate uptake (n = 2). These
data suggested that KA and DHK selectively block uptake mediated by the EAAT2 subtype without serving as substrates for
uptake.
The mechanism of KA and DHK inhibition of EAAT2-mediated glutamate uptake was examined in greater detail by studying the effect of increasing concentrations of KA and DHK on
the kinetic parameters for the L-glutamate uptake currents. Concentration-response
curves to glutamate in the presence of 30
PM, 100 PM, or 300 PM KA were fitted to the Michaelis-Menten
expression, and the glutamate concentration-response
curves
were shifted in a parallel manner (Fig. 6B). Similar data was
obtained with DHK, suggesting that KA and DHK are competitive antagonists of EAAT2-mediated uptake. Schild analysis
(Fig. 6C) provided estimates of the KA and DHK equilibrium
dissociation constants as 16.7 PM and 9.2 PM, respectively (Table
2).

Discussion
Three members of a gene family that mediate high-affinity sodium-dependent glutamate uptake were identified by molecular
cloning from human motor cortex. The isolation of the EAAT 1,
EAAT2, and EAAT3 cDNA sequences provides the means to
express and characterize the properties of these transporters,
which previously have been difficult to isolate functionally and
study. The present study directly compares the sequence, distribution, and function ofthis human glutamate transporter gene
family to identify similarities and differences reflecting the intrinsic properties of each subtype.
The regional distributions of EAATl, EAAT2, and EAAT3
RNAs were compared in brain and in peripheral tissues by
Northern blot analyses. Because of their postulated role in synaptic transmission, there is considerable interest in defining the
particular cell types and neuronal pathways in which glutamate
transporter subtypes are expressed. The rat transporters GLASTl
(Storck et al., 1992) and GLTl (Danbolt et al., 1992; Pines et
al., 1992; Levy et al., 1993) were reported to be expressed by
glia, while EAACl in brain was localized to neurons (Kanai and
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Figure 5. Electrogenic
uptakein oocytesexpressing
EAAT subtypes.
A, Inward currentswere elicited by the applicationof substrates
to
oocytesinjectedwith synthetictransporterRNAs andvoltageclamped
at -60 mV. Dose-dependent
and saturableresponses
to L-glutamate
areshownfor an oocyteexpressing
EAAT3. No uptakecurrentswere
observedwhensodiumwasreplacedwith choline(Na+-free).Superfusion of the sameoocyte with PDC, a glutamateuptakeinhibitor,
evokedresponses
with propertiessimilarto glutamateuptakecurrents.
PDC, like most of the inhibitory compoundstested,is a glutamate
transportersubstrate.
B, Uptakecurrentsmeasured
for L-glutamate
and
PDCwerenormalizedto the maximumL-glutamate
currentdetermined
in the sameoocyte,and fitted to the Michaelis-Mentenequation.The
kineticparameters
listedin Table2 for PDCandothersubstrates
were
obtainedby this method.

Hediger, 1992). Sequence similarities initially suggestedthat
EAATl and GLASTl, EAAT2 and GLTl, and EAAT3 and
EAACl could be subtype counterparts in different species.Comparisons of our Northern distributions with those previously
reported support the EAATyGLT 1correspondenceand suggest
that EAAT2 may be expressedin glia. However, differencesin
peripheral tissue distributions make the subtype correspondencesof EAAT 1/GLAST 1and EAAT3/EAAC 1lesslikely, and
recent work in our laboratory that suggeststhe existence of
additional subtypes makesthe assignmentof specieshomologs
uncertain. Although our Northern blot analysesdo not provide
cellular resolution, they do provide insight into several aspects
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, EAATP,

2.

and

Kinetic

EAAT3

parameters

of uptake

in oocytes

EAATl

Substrate

Km (PM)

EAAT2

Imax’

L-Glutamate 20 * 3
L-Aspartate 16 + 1
D-Glutamate 595 + 50
D-Aspartate 23 + 2
TOHA
33 zk 3

(1)

PDC
KA

-

0.52
-

DHK

-

-

28 f 2

0.68

+ 0.01

1.10k 0.06
0.43
0.55

EAAT3

Km (~4
18 + 3
7&l
5360

k 420

I maxa

Km (PM)

Inn.,”

(1)
0.89

28 k 6
24 f 2
1781 + 68

(1)
0.95
0.66

47 -t 8
37 -t 1
27 + 5

0.82
0.94
0.34
-

-+ 0.00
* 0.01

13 I? 1
10 + 1

0.20
0.84
0.33

k 0.05

7to
16.7*

0.35
(0)

9.2b

(0)

+ 0.04
k 0.04
f 0.02
+ 0.02
+ 0.01

-

+ 0.03
+ 0.04
-t 0.07
+ 0.01
f 0.01

o Lax is normalized to the L-glutamate I,,,,, in the same oocyte.
b Determined
by Schild analysis; KA and DHK did not induce currents.

of EAAT mRNA expression.Expressionof EAAT 1and EAAT3
is not restricted to the brain, suggestinga role in nutrient uptake
in other tissues.Moreover, the mRNA content of each EAAT
subtype observed in different brain regions does not correlate
well with the prevalence of glutamatergic neurons. Notably,
EAAT subtypeswere as abundant in the basalgangliaas in the
hippocampus. Although the basal ganglia contains few glutamatergic neurons,extensive glutamatergic innervation may necessitateglial transporter functions. Alternatively, the participation of glutamate transporters in the metabolic uptake of
acidic amino acids is observed in most tissues,and such functions may be attributed to EAAT subtypes in the brain. Assignment of functional roles in metabolism and/or synaptic
function to individual subtypesawaitsthe determination of cell
type specificity by histochemical analyseswith cellular resolution.
EAATl, EAAT2, and EAAT3 exhibit striking amino acid
sequencesimilarities, and it could be that their structural diversity has been sharply constrained by the functional complexity of the uptake process.The translocation of glutamate
acrossthe cell membraneinvolves the binding and movement
of substrate,but this processis alsocoupled to the cotransport
of several Na+ ions (Balcar and Johnston, 1972) and probably
the countertransport of intracellular K+ (Kanner and Sharon,
1978; Barbour et al., 1988) and OH- ions (Erecinska et al.,
1983; Bouvier et al., 1992). The transmembrane topology of
this family of membrane-bound glycoproteins is currently unresolved, with both 8 (Pines et al., 1992) and 10 (Kanai and
Hediger, 1992)transmembraneregionsmodelshaving beenproposed previously. In comparing the sequencesof the EAAT
subtypes,we find that structural conservation is prevalent within, but not limited to, nine large hydrophobic regions(Fig. 1).
Particularly well conservedare the sequencesin the vicinity of
the seventhand eighth hydrophobic region which includesboth
a serine-rich sequencemotif and the conserved AA(I/V)FIAQ
structural motif utilized to isolate thesegeneproducts. The serine-rich sequence(SSSS in EAATl and EAAT3, ASSA in
EAAT2) is similar to a sequenceinvolved in glutamate binding
to metabotropic glutamate receptors (CYHara et al., 1993). If
this motif should comprise a portion of the transporter glutamate binding site, these sequencedifferences could be related
to the differential sensitivities of EAATl/EAAT3
and EAAT2
to several uptake inhibitors (seebelow).
The molecularcloning of three glutamate transporter subtypes
from a single specieshas enabled a direct comparison of their

functional and pharmacologicalproperties. Here, the functional
properties of the human subtypes were compared in two different assaysystems.Measurements of the radiolabeled L-glutamate uptake mediated by each EAAT subtype in transfected
mammalian cellsyielded K,,, values that varied between48 and
97 PM. The ion flux that accompaniesglutamatetransport results
in inward currents that were measuredin voltage-clamped oocytes expressingeach EAAT subtype. Km determinations by
measurementof transport currents in oocytes were comparable
to those determined by uptake in mammalian cells, although
generally of higher affinity (18-28 PM). System differencesmight
be attributed to differences in lipid composition, posttranslational modifications, or other factors. Similar differences are
found in the literature when uptake by synaptosomalor other
membrane preparations are compared with whole cell uptake.
Thus, differencesbetweenL-glutamate K,,, values previously reported for cloned glutamate transporter subtypes may in part
be due to the different assaysused. The reported Km for radiolabeledglutamate uptake by GLAST 1 expressedin oocytes was
77 PM (Storck et al., 1992) whereasGLTl was reported to have
a K, of 10 PM for uptake in intact mammalian cells and 2 PM
in membrane preparations (Pines et al., 1992) and EAACl
yielded a glutamate K,,, of 12 PM as determined by oocyte electrophysiology (Kanai and Hediger, 1992). Basedon the higher
reported K,,,, it was suggestedpreviously that GLASTl might
function as a low-affinity reserve uptake system (Kanai et al.,
1993). The human glutamate transporters may have functional
differencesfrom those of other species,but our measurements
provided little evidence for significant subtype differences in
affinity for L-glutamate.
A glutamate transporter pharmacology largely developed in
rat synaptosomalpreparation (Ferkany and Coyle, 1986;Fletcher and Johnston, 1991; Robinson et al., 1991, 1993)wasapplied
to the cloned EAAT subtypes.Surprisingly, we found that a-aminoadipate (aAA) exhibited very low potency in inhibiting glutamate uptake by the EAAT subtypes.This result contrastswith
findings in rat cerebellar synaptosomeswhere an IC,, of 20-40
PM was determined for aAA (Robinson et al., 1991, 1993),and
with the previously reported sensitivity of cloned GLTl and
EAACl to this compound (Kanai and Hediger, 1992; Pines et
al., 1992). ODAP, quisqualate and P-p-chlorophenylglutamic
acid are other compoundsreported to inhibit transport that were
of low potency in our assays.ODAP was reported to potently
inhibit transport in rat and primate synaptosomes(Lakshmanan
and Padmanaban, 1974b), and it is the excitotoxin implicated
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Figure 6. Kainateand dihydrokainateare competitiveblockersof EAATZ-mediateduptake.A, The applicationof KA (100 PM)did not elicit

currentsin oocytesexpressing
eitherEAATl, EAATZ, or EAAT3. However,thecurrentselicitedby L-glutamate
(100PM)wereinhibitedsignificantly
by the coadministration
of KA in oocytesexpressing
EAAT2, but not EAATl or EAAT3. Thesedataconfirmthat KA selectivelyblocksEAATZmediatedglutamateuptake.B, Dose-dependent
inwardcurrentselicitedby the superfusion
of EAATZ-expressing
oocyteswith L-glutamate(circles)
undergoparallelshiftswith theadditionof 30 PM(triangles), 100PM(diamonds),
or 300PM(squares) of KA. Moreover,KA inhibitionwasabolished
at highglutamateconcentrations.Thesedata indicatethat KA competitivelyblocksEAAT2-mediateduptake.C, The antagonistequilibrium
dissociation
constantsof KA (solid diamonds) and DHK (open diamonds) wereestimatedfrom Schildplots. The agonistdoseratio (r) at each
antagonistconcentrationwascalculatedfrom the data shownin B for KA, andfrom similarDHK data not shown.Eachline wasfit to the data
by leastsquares
andwith a slopeof 1, andthe KA andDHK K, valuesgiven in Table2 wereobtainedfrom the abscissa1
intercept.

in the human degenerative diseaselathyrism (Spencer et al.,
1986). These results may suggestpharmacological differences
between the human subtypes and those of other species,but
also indicate that other EAAT subtypes or glutamate transport
systemsexist. Regional differencesin pharmacology have suggestedthe existence of at least four glutamate transporter subtypes (Robinson et al., 1993), and distinct glutamate uptake
systemshave also been described.
The EAAT subtypesfall into two distinct groupingsbasedon
differencesin uptake inhibitor pharmacology.EAAT2-mediated
uptake in mammalian cells was 7-IO-fold more sensitive to
PDC than the EAATl and EAAT3 subtypes (Table 1). The
EAATl/EAAT3 subtypes,on the other hand, were much more
potently inhibited by SOS than was EAAT2. Pharmacological
distinctions betweenthe EAAT2 and EAATl/EAAT3 subtypes,
however, were most clearly demonstrated by KA and DHK.
EAAT2-mediated transport in COS-7 cellswasinhibited by KA
and DHK with K, values of 23 and 59 PM, respectively, but
these agentsdid not significantly affect uptake by EAATl or
EAAT3. Compounds suchas PDC were determined to be substratesbecausethey elicited specificuptake currents in oocytes
expressingthe EAAT subtypes. KA and DHK, on the other
hand, did not evoke currents via any.EAAT subtype, and these
compounds were found to inhibit only the glutamate uptake
currents mediated by EAAT2. It has been reported previously
that KA and DHK are not transport substrates(Lakshmanan

and Padmanaban, 1974a;Johnston et al., 1979), and that both
compounds, but particularly DHK, inhibit glutamate uptake
with the greatest potency in synaptosomesprepared from rat
striatum (Robinson et al., 1991, 1993). EAAT2 mRNA wasthe
most abundant subtype transcript in human basalganglia, and
we identify this as a KA/DHK-sensitive subtype.
The structure of the glutamate conformer that binds to sodium-dependent glutamate transporters has been studied using
structurally constrained glutamate analogs (Chamberlin and
Bridges, 1993; Bridges et al., 1993). Thesestudiesutilized synaptosomal preparations likely to contain mixed subtypes, and
the application of thesestructural conceptsto the pharmacology
of the cloned transporter subtypesis of interest. PDC, KA, and
DHK are glutamate analogsthat can be viewed ascontaining a
similar embedded glutamate conformer, but differing by the
addition of isopropenyl or isopropyl groups at the 4-positions
of KA or DHK, respectively (Bridges et al., 1993; Chamberlin
and Bridges, 1993). We found PDC to be a substrate of each
EAAT subtype. KA/DHK did not interact with EAATl and
EAAT3, possibly becauseof steric inhibition by the additional
alkyl groups. The binding of KA/DHK to EAAT2, on the other
hand, occurswith high affinity (equilibrium constantsof 17and
9 PM, respectively, in oocytes), but theseagentscannot undergo
membrane translocation. Structural differences between the
EAAT2 and EAATl/EAAT3
substratebinding sitesshould be
identifiable that give rise to thesedistinct pharmacologies.None
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of the compounds that we have tested thus far provide such a
clear distinction between the properties of EAATl and EAAT3,
and this is an additional area for further investigations.
In addition to the activation of glutamate receptors, the interactions of excitatory amino acids and their analogs with higbaffinity uptake systems can be a significant determinant
of their
neurotoxicity
(Choi et al., 1987; Rosenberg et al., 1992). The
toxicity of TPHA, a high-affinity
substrate for each EAAT subtype, may be due in part to the inhibition
of glutamate uptake
(McBean and Roberts, 1985). KA is one of the most potent
neurotoxins known, and its toxicity relative to glutamate is likely

to be enhancedbecauseit is not readily taken up (Garthwaite,
1985). The weak inhibition
of glutamate uptake described in
rat brain synaptosomes by KA (Lakshmanan
and Padmanaban,
1974a; Robinson et al., 1993) and the potent inhibition
of the
EAAT2
subtype demonstrated
here may be additional
component in KA toxicity. Lesion studies in the rat striatum have
shown glutamatergic
innervation
to be essential for KA toxicity
(McGeer et al., 1978), and elevated glutamate levels due to KA
inhibition
of uptake could provide an essential component
of
neurotoxicity.
These data suggest the importance of understanding the interactions
of excitatory amino acids and their analogues with the various transport systems. The cloning and functional assays utilized here to characterize EAAT 1, EAAT2, and
EAAT3 provide a basis for future research into the structure,
function, and pharmacology
of these transporters.
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